| Literature DB >> 25073652 |
Issaka Sagara1, Roch Giorgi, Ogobara K Doumbo, Renaud Piarroux, Jean Gaudart.
Abstract
BACKGROUND: Recurrent events data analysis is common in biomedicine. Literature review indicates that most statistical models used for such data are often based on time to the first event or consider events within a subject as independent. Even when taking into account the non-independence of recurrent events within subjects, data analyses are mostly done with continuous risk interval models, which may not be appropriate for treatments with sustained effects (e.g., drug treatments of malaria patients). Furthermore, results can be biased in cases of a confounding factor implying different risk exposure, e.g. in malaria transmission: if subjects are located at zones showing different environmental factors implying different risk exposures.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25073652 PMCID: PMC4132199 DOI: 10.1186/1475-2875-13-293
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Data structures for modelling recurrent time-to-event outcomes
| 1 | 0 | 28 | 1 | 1 | 28 | AS + SP | 3.93 | 1 |
| 1 | 42 | 52 | 1 | 2 | 10 | AS-SP | 3.93 | 1 |
| 1 | 476 | 700 | 0 | 10 | 224 | AS + SP | 3.93 | 1 |
| 2 | 0 | 77 | 1 | 1 | 77 | AS + AQ | 1.15 | 1 |
| 2 | 91 | 375 | 1 | 2 | 284 | AS + AQ | 1.15 | 1 |
| 2 | 417 | 700 | 0 | 4 | 283 | AS + AQ | 1.15 | 1 |
| 3 | 0 | 28 | 1 | 1 | 28 | AL | 1.48 | 1 |
| 3 | 42 | 78 | 1 | 2 | 36 | AL | 1.48 | 1 |
| 3 | 150 | 700 | 0 | 5 | 550 | AL | 1.48 | 1 |
Data dictionary:
ID: study subject identification number; start: the start time of the interval (in days); end: the time (in days) at which the event occurs or the time of censoring; episode, the occurrence of malaria episode (yes = 1, no = 0); order: the order of the episodes, which is used only for the PWP-CP model; time: the number of days at risk that is calculated from subtracting end from start variables; treatment: the same malaria treatment given to the patient during each episode; Age (Years): the patients age at enrolment in years; quarter: the resident place or bloc of the patient in the village (old quarter = 1, new quarter = 0).
Coefficient estimates according to model by discontinuous risk intervals analysis
| GEE, Poisson distribution | 1.02 (0.044); [0.93-1.11]; p = 0.722 | 0.93 (0.029); [0.87- 0.99]; p = 0.018 | 1.36 (0.201); [1.02-1.82]; p = 0.036 | 1.22 (0.181); [0.91-1.63]; p = 0.175 |
| AG-CP | 0.75 (0.068); [0.62-0.89]; p < 0.001 | 0.74 (0.065); [0.62-0.88]; p < 0.001 | 3.16 (0.621); [2.15-4.65]; p < 0.001 | 2.61 (0.526); [1.76-3.88]; p < 0.001 |
| PWP-CP | 0.86 (0.055); [0.76-0.97]; p = 0.015 | 0.85 (0.052); [0.75-0.96]; p = 0.007 | 2.34 (0.389); [1.69-3.24]; p < 0.001 | 2.04 (0.345); [1.46-2.84]; p < 0.001 |
| Shared gamma frailty | 0.76 (0.064); [0.64-0.89]; p = 0.001 | 0.74 (0.063); [0.62-0.87]; p < 0.001 | 3.04 (0.458); [2.27-4.09]; p < 0.001 | 2.54 (0.397); [1.87-3.45]; p < 0.001 |
*Reference treatment: AL.
**Reference age group: >9 years old.
CI: Confidence interval for RR/HR (Relative risk/Hazard ratio); SE: Standard error; p: p value.
Coefficient estimates according to model by continuous risk intervals analysis
| GEE, Poisson distribution | 1.02(0.044); [0.93-1.11]; p = 0.722 | 0.93 (0.029); [0.87- 0.99]; p = 0.02 | 1.36 (0.201); [1.02-1.82]; p = 0.04 | 1.22 (0.181); [0.91-1.63]; p = 0.18 |
| AG-CP | 0.77 (0.064); [0.65-0.91]; p = 0.002 | 0.76 (0.062); [0.65-0.89]; p = 0.001 | 2.94 (0.559); [2.03-4.27]; p < 0.001 | 2.48 (0.481); [1.69-3.62]; p < 0.001 |
| PWP-CP | 0.83 (0.053); [0.73-0.94]; p = 0.004 | 0.81 (0.050); [0.72-0.92]; p = 0.001 | 2.35 (0.388); [1.71-3.26]; p < 0.001 | 2.05 (0.344); [1.48-2.85]; p < 0.001 |
| Shared gamma frailty | 0.77 (0.061); [0.66-0.90]; p = 0.001 | 0.76 (0.060); [0.65-0.89]; p < 0.001 | 2.88 (0.415); [2.17-3.82]; p < 0.001 | 2.43 (0.364); [1.82-3.26]; p < 0.001 |
*Reference treatment: AL.
**Reference age group: >9 years old.
CI: Confidence interval for RR/HR (Relative risk/Hazard ratio); SE: Standard error; p: p value.
Incidence rate* per treatment arm according to discontinuous or continuous risk intervals analysis
| Discontinuous time risk intervals | 2.01 [1.86-2.17] | 1.52 [1.39-1.66] | 1.50 [1.37-1.64] |
| Continuous time risk intervals | 1.87 [1.73-2.02] | 1.44 [1.32-1.57] | 1.42 [1.30-1.55] |
| 0.09 | 0.19 | 0.19 |
*Malaria episodes/person/year.
IR: Incidence rate; CI: Confidence interval for IR; p-values: Exact mid p-values for risk difference between discontinuous and continuous risk intervals.
Figure 1Coefficients estimate using observed and simulated data using discontinuous risk intervals analysis. Dark dots with lines are Relative risk/Hazard ratio and their 95% Confidence intervals respectively; Vertical central dark line is either the no effect treatment line compared to the referent category (artemether-lumefantrine) or the no effect age group compared the referent category (age group > 9 years old). Abbreviations: AS + AQ, artesunate + amodiaquine; AS + SP, artesunate + sulphadoxine-pyrimethamine; AG, Andersen-Gill; PWP, Prentice-Williams-Peterson; GEE, generalized estimating equation; SE, standard error; ECR, empirical coverage rate.